<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lori R Holtz, MD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Phillip I Tarr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H821540695"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Escherichia coli</em> that contain genes encoding Shiga toxins 1 and/or 2 are important human pathogens. Some of them, such as <em>E. coli</em> O157:H7, cause severe disease, most notably painful bloody diarrhea, and the hemolytic uremic syndrome (HUS). These Shiga toxin-producing <em>E. coli</em> (STEC) infect people of all ages, but children under 10 years old and older adults have the most severe courses. Optimal management entails provider awareness at the point of presentation, rapid and accurate diagnostic microbiology, intravenous (IV) volume expansion, judicious and strategic laboratory testing, avoidance of potentially harmful interventions (eg, antibiotics and agents that impair gut motility or renal blood flow), careful monitoring, and engagement of public health disease control authorities. </p><p>Most clinical data on STEC infections are derived from studies in children. Most of the recommendations in this topic are thus informed by these data and our personal experience managing infection in children. However, STEC infections, HUS, and even fatal HUS can affect people of all ages. Clinical experience and the limited data on adult patients suggest a largely similar course of STEC infection among children and adults, with few substantial differences [<a href="#rid1">1</a>]. Thus, our recommendations refer to both children and adults unless otherwise specified. </p><p>The clinical manifestations, diagnosis, and management of STEC infections (prior to HUS) are discussed here, focusing on the diarrheal phase of illness. The microbiology and epidemiology of STEC infections are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention"</a>.)</p><p>Issues related to STEC-associated HUS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a>.)</p><p class="headingAnchor" id="H4282588105"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>STEC fall into two clinically relevant categories: those that contain a gene encoding Shiga toxin 2 (with or without a gene encoding Shiga toxin 1) and those that do not (ie, their only Shiga toxin gene encodes Shiga toxin 1)  (<a class="graphic graphic_table graphicRef120224" href="/z/d/graphic/120224.html" rel="external">table 1</a>). STEC containing Shiga toxin 2 and its allelic variants are more virulent than those containing only Shiga toxin 1 and/or its variants. STEC that contain the gene encoding Shiga toxin 2 are often associated with bloody diarrhea and can cause hemolytic uremic syndrome (HUS) independent of serogroup, whereas those that only contain the gene encoding Shiga toxin 1 are very rarely associated with bloody diarrhea and carry minimal or no risk for HUS. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Shiga toxin type'</a>.)</p><p>Almost all <em>E. coli</em> O157:H7 contain a gene encoding Shiga toxin 2 (and about two-thirds additionally contain a gene encoding Shiga toxin 1) [<a href="#rid2">2,3</a>]. This serotype remains a leading cause of STEC infections worldwide and is the serotype most likely associated with epidemics and severe disease. Many STEC that belong to other serotypes (ie, non-O157:H7 STEC) contain a gene encoding Shiga toxin 1 but not Shiga toxin 2; only a subset of these non-O157:H7 serotypes isolated from humans have the capacity to produce Shiga toxin 2 and cause severe disease. Paradoxically, among STEC that contain a gene encoding Shiga toxin 2, those that also contain a gene encoding Shiga toxin 1 have somewhat lower risk of progressing to HUS [<a href="#rid4">4,5</a>].</p><p>In this topic, the term "high-risk STEC" refers to <em>E. coli</em> O157:H7 and the subset of non-O157:H7 serotypes that contain a gene encoding Shiga toxin 2. This includes sorbitol-fermenting <em>E. coli </em>O157:NM, a pathogen largely confined to Germany and the Czech Republic. Although most clinical literature pertains to infections caused by <em>E. coli</em> O157:H7, the data can be confidently extrapolated to apply to infections caused by any non-O157:H7 STEC that contains a gene encoding Shiga toxin 2. </p><p>The terminology of STEC, which can be confusing and problematic, is also reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">"Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Microbiology'</a>.)</p><p class="headingAnchor" id="H2522116153"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1738513197"><span class="h2">Incubation period</span><span class="headingEndMark"> — </span>Following exposure, STEC infections have a median incubation period of three days, with a range of 1 to 10 days. This estimate is based on <em>E. coli</em> O157:H7 outbreaks in which the time and date of the exposure can be determined [<a href="#rid6">6</a>]. However, many STEC infections cannot be linked to a specific vehicle or exposure, so the exact timing of ingestion is often unknown. </p><p class="headingAnchor" id="H4228235144"><span class="h2">Typical clinical findings</span><span class="headingEndMark"> — </span>Infections with high-risk STEC (ie, all <em>E. coli</em> O157 and any non-O157 STEC that encodes a gene for Shiga toxin 2) are typically characterized by painful diarrhea that becomes bloody, often without persistent fever. (See <a class="local">'Terminology'</a> above.)</p><p>The course of infection with high-risk STEC follows a patterned sequence of events  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. We consider the first day of illness to be the first day of diarrhea (and we base management decisions on the day of illness  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>)), although abdominal pain, vomiting, and fever can precede the onset of diarrhea. The initially nonbloody diarrhea typically becomes visibly bloody one to three days after onset; however, approximately 15 to 20 percent of patients with <em>E. coli</em> O157:H7 experience only nonbloody diarrhea (data are sparser for high-risk non-O157 STEC). Uncommonly, patients with <em>E. coli</em> O157:H7 report only a few hours of nonbloody diarrhea before the stool becomes visibly bloody or, even more rarely, state that the first loose stool was bloody [<a href="#rid8">8</a>]. Diarrhea generally resolves after about seven days. </p><p>Hemolytic uremic syndrome (HUS), if it occurs, is usually established 5 to 13 days after the onset of diarrhea. In rare cases, patients infected with high-risk STEC have no diarrhea but still develop HUS [<a href="#rid9">9-11</a>]. (See <a class="local">'Hemolytic uremic syndrome'</a> below.)</p><p>It is very unusual for patients with STEC infection to be febrile at presentation, but many patients or their families or caregivers report a fever early in the illness, prior to seeking care. As an example, in a retrospective review of 260 cases of STEC infection, fever was self-reported in approximately 30 and 16 percent of O157:H7 and non-O157 <em>E. coli</em> cases, respectively [<a href="#rid12">12</a>], but despite such reports of pre-presentation fever, documented fever in medical settings is quite uncommon [<a href="#rid13">13</a>]. Absence of fever at presentation does not distinguish infections caused by <em>E. coli</em> O157:H7 from other bacterial enteric infections [<a href="#rid14">14</a>]. Nevertheless, high fever (&gt;38.5°C) in a patient with painful diarrhea makes other pathogens (eg, <em>Shigella</em>, <em>Campylobacter</em>, or <em>Salmonella</em>) the more likely etiologic agents. (See <a class="local">'Clinical suspicion'</a> below.)</p><p>Other highly prevalent features of <em>E. coli</em> O157:H7 infection include abdominal pain and an acute onset [<a href="#rid8">8,15</a>]. However, these do not distinguish high-risk STEC infections from bloody diarrhea caused by other pathogens [<a href="#rid14">14</a>].</p><p>When bloody diarrhea first develops during a high-risk STEC infection, the platelet count, creatinine concentration, and hematocrit are typically normal, and there is no evidence of hemolysis on peripheral blood smear. However, abnormalities in coagulation and fibrinolysis suggestive of vascular injury are present at this early point in illness and, as infection progresses, the platelet count often falls, sometimes to values below the lower limit of normal, even if the patient does not develop HUS [<a href="#rid16">16-20</a>]. We use the day-to-day trend in platelet counts as indicators of risk of HUS, or of resolution. (See <a class="local">'Timing of fluid discontinuation and discharge'</a> below.)</p><p class="headingAnchor" id="H506336238"><span class="h2">Complications</span></p><p class="headingAnchor" id="H3543613202"><span class="h3">Hemolytic uremic syndrome</span><span class="headingEndMark"> — </span>The most consequential complication of STEC infection is hemolytic uremic syndrome (HUS). HUS is characterized and diagnosed by the triad of nonimmune-mediated hemolytic anemia, thrombocytopenia, and acute kidney injury (we recommend thresholds of hematocrit &lt;30 percent, platelet count &lt;150,000/microL, and serum creatinine greater than the upper limit of normal for age). </p><p>The likelihood that a patient infected with <em>E. coli</em> O157:H7 develops HUS varies by age. Fifteen to 20 percent of children younger than 10 years with culture-proven <em>E. coli</em> O157:H7 infection develop HUS. The HUS rate after childhood is difficult to determine with certainty because ascertainment of infection rates might differ between children and adults, and STEC-associated HUS may be misclassified in adults as atypical HUS or thrombotic thrombocytopenic purpura. Nevertheless, although the incidence of diagnosed STEC infection falls markedly during and after adolescence, STEC infections that occur in adults are not categorically less serious than those in children. As an example, in a 2018 North American outbreak in which the majority of the 210 infected cases were adults, 96 were hospitalized, 27 developed HUS, and five died [<a href="#rid21">21</a>].</p><p>Patients who develop HUS generally meet the case definition on a median of day 7 to 7.5 of illness, with a range between 5 and 13 days (the first day of illness is the first day of diarrhea  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>)) [<a href="#rid22">22,23</a>]. We have occasionally treated patients infected with <em>E. coli</em> O157:H7 who develop HUS on day 4 after the onset of diarrhea. Rarely, patients with HUS caused by a high-risk STEC <em>E. coli</em> have no diarrhea [<a href="#rid9">9-11</a>]. </p><p>The clinical manifestations and diagnosis of STEC-associated HUS are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Typical course'</a> and  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2012794098"><span class="h3">Other</span><span class="headingEndMark"> — </span>Rarely, patients with STEC infection present with intussusception [<a href="#rid24">24</a>]. In some institutions, antibiotics are administered before nonoperative reduction of intussusception, but in cases of intussusception associated with STEC, we discourage using antibiotics. (See <a class="local">'Antibiotics'</a> below.)</p><p>Intussusception is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5898.html" rel="external">"Intussusception in children"</a>.)</p><p class="headingAnchor" id="H2461685586"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H332804854"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>Infections with high-risk STEC (ie, <em>E. coli</em> O157:H7 or non-O157 STEC that encode a gene for Shiga toxin 2) should be suspected in the following [<a href="#rid9">9-11</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>All patients of all ages with acute bloody diarrhea. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who develop diarrhea (even if nonbloody) after contact with a patient with known STEC infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with hemolytic uremic syndrome (HUS), even if they do not have diarrhea. </p><p></p><p>Because high-risk STEC cause severe illness, we presumptively manage all patients with clinical suspicion for STEC infection as having infection, pending microbiologic testing. However, some features decrease the likelihood of a high-risk STEC infection  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>). Such features are:</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea that abates within several hours of presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Total duration of nonbloody and bloody diarrhea greater than one week at time of presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Findings that suggest a chronic process (eg, microcytic anemia, weight loss)</p><p class="bulletIndent1"><span class="glyph">●</span>Contact with a patient with non-STEC bacterial colitis</p><p></p><p>Fever (arbitrarily &gt;38.5°C or &gt;101.3°F) at the time of presentation is also atypical but, if present, should not be used to discount the possibility of STEC infection. </p><p>We strive to confirm or refute a high-risk STEC infection with microbiologic testing as early in illness as possible. This is important because early diagnosis facilitates focused treatment. In general, prior to definitive diagnosis we err on the side of inpatient management, with the recognition that most individuals with acute bloody diarrhea do not have a high-risk STEC infection. Our approach includes at least a six-hour observation period. If, in that interval, abdominal pain abates or greatly diminishes, or the diarrhea becomes nonbloody, decreases in volume, or stops entirely, accelerated discharge with follow-up as an outpatient may be appropriate. </p><p>During this observation period, we commence management of presumptive high-risk STEC infection with aggressive intravenous (IV) volume expansion  (<a class="graphic graphic_figure graphicRef121336" href="/z/d/graphic/121336.html" rel="external">figure 2</a>). Stopping points include improvement within hours of admission and exclusion of a high-risk STEC infection by microbiologic testing  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>). Rapid nonculture diagnostics can detect STEC within several hours, thereby reducing admissions and overtreatment of individuals with bloody diarrhea from non-STEC infections. (See <a class="local">'Microbiologic diagnosis'</a> below.)</p><p>Our approach to management of suspected and documented STEC infection is discussed in detail below. (See <a class="local">'Management'</a> below.)</p><p>Children with STEC infection often have symptoms severe enough to present to emergency departments but account for a small proportion of patients with acute diarrhea in that setting; thus, they are often not recognized as having STEC and being at risk for HUS. In one study of children with STEC presenting to pediatric emergency departments in the United States and Canada, one in seven developed HUS within a median of three days of that visit, and nearly 30 percent of those who subsequently developed HUS were initially sent home [<a href="#rid25">25</a>]. </p><p class="headingAnchor" id="H715329943"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The initial evaluation of patients with suspected STEC infection includes determination of the stage of disease, basic laboratory testing, and microbiologic testing for STEC and other bacterial pathogens associated with bloody diarrhea on rectal swab or stool specimens:</p><p class="bulletIndent1"><span class="glyph">●</span>When asking about presenting symptoms, we emphasize determining the first day that the patient experienced loose stools. We then designate this day as the first day of illness  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>). Prodromal symptoms such as vomiting or abdominal pain often precede the first day of diarrhea; however, they are too nonspecific to serve as points of reference for subsequent phases of illness [<a href="#rid26">26</a>]. We also ask about visible blood in the stools and abdominal pain. On physical examination, we focus on vital signs, heart and lung auscultation (in anticipation of aggressive volume expansion), and abdominal examination. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We check the complete blood count, electrolytes, and serum creatinine at presentation and use these data as baselines for reference on subsequent days. It is important to pursue focused testing, with careful interpretation of the results [<a href="#rid26">26,27</a>]. As an example, an abnormal urinalysis might prompt treatment of a presumed urinary tract infection, despite the likelihood that an abnormal urinalysis in the setting of infectious diarrhea in a young child reflects contamination of urine with stool. Serum lactate dehydrogenase (LDH) has been used to monitor progression and resolution of established thrombotic microangiopathies of various etiologies and could be a harbinger of hemolysis [<a href="#rid25">25</a>], but data are insufficient to guide fluid treatment based on LDH concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid and accurate microbiologic testing is critical for the management of suspected STEC infections and is an essential component of the initial evaluation. Specimen collection and microbiologic testing for STEC are outlined below. (See <a class="local">'Microbiologic diagnosis'</a> below.) </p><p></p><p>Computed tomography (CT) rarely, if ever, has a role in evaluating suspected or documented STEC infections in children; the low likelihood that the findings could inform management is outweighed by the risks of ionizing radiation and the potential nephrotoxicity of IV contrast. In adults, however, in whom noninfectious intestinal disorders can present with bloody diarrhea, CT (and other testing) might have value [<a href="#rid28">28</a>]. Nevertheless, in all cases of acute bloody diarrhea in adults, prompt and thorough microbiologic assessment is of paramount importance.</p><p>The initial evaluation of patients with acute diarrhea in general is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">"Diagnostic approach to diarrhea in children in resource-abundant settings", section on 'Acute diarrhea (typical duration &lt;5 days)'</a> and  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H1844116960"><span class="h2">Microbiologic diagnosis</span></p><p class="headingAnchor" id="H3496584091"><span class="h3">Specimen collection</span><span class="headingEndMark"> — </span>When STEC is suspected, stool should be submitted for bacterial enteric pathogen testing as a matter of priority. Unless the patient can immediately produce a stool specimen, we suggest obtaining a rectal swab specimen given the importance of an expedited diagnosis. Furthermore, in the rare patient with HUS but no diarrhea, a rectal swab culture might be the only way to establish the diagnosis of an STEC infection. In one study of children with diarrhea, rectal swab specimens were associated with higher pathogen yields than stool specimens [<a href="#rid29">29</a>]. </p><p>The Infectious Diseases Society of America (IDSA) recognizes the value of swab cultures of stool in children but does not yet endorse such a strategy for adults because of concerns about sensitivity [<a href="#rid30">30</a>]; however, in our center, swab specimens had similar yields of bacterial enteric pathogens to bulk specimens at all ages, and results were obtained sooner [<a href="#rid31">31</a>]. Hence, we also encourage rectal swab specimens in adults with bloody diarrhea if a bulk stool cannot be obtained, as a rectal swab culture can accelerate the time to microbiologic diagnosis [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H1075169842"><span class="h3">Detecting STEC</span><span class="headingEndMark"> — </span>The rectal swab or stool specimen should be submitted for selective culture for <em>E. coli </em>O157:H7 and Shiga toxin testing, either by immunoassay following overnight broth culture or by molecular technology [<a href="#rid32">32</a>]. </p><p>The diagnosis of STEC infection is made in a patient with acute diarrhea when <em>E. coli</em> O157:H7 is isolated and/or when Shiga toxin (or a gene encoding a Shiga toxin) is detected. If a Shiga toxin or Shiga toxin gene is detected but <em>E. coli</em> O157:H7 is not identified, it is important to determine if the STEC produces Shiga toxin 2, as this indicates a high-risk STEC and has prognostic and management implications. Until the toxin genotype is known, we take a cautious approach and consider an unspecified Shiga toxin signal from a patient with acute diarrhea to reflect a high-risk STEC pathogen  (<a class="graphic graphic_figure graphicRef121336" href="/z/d/graphic/121336.html" rel="external">figure 2</a>). (See <a class="local">'Terminology'</a> above.) </p><p>Available testing may vary by clinical laboratory, and each has advantages and drawbacks  (<a class="graphic graphic_table graphicRef120223" href="/z/d/graphic/120223.html" rel="external">table 2</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective culture</strong> – All patients with suspected STEC infection should have specimens submitted to recover this pathogen. As <em>E. coli</em> O157:H7 remains a major high-risk STEC in much of the world, we encourage the plating of all stools on selective sorbitol-MacConkey (SMAC) agar (with or without <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a> and tellurite). This serotype ferments <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> slowly and appears as translucent colonies on this medium  (<a class="graphic graphic_picture graphicRef82227" href="/z/d/graphic/82227.html" rel="external">picture 1</a>). Such colonies can be confirmed as <em>E. coli</em> biochemically and tested for reaction with antisera to the O157 antigen. Strains presumptively identified as <em>E. coli</em> O157:H7 should be sent to a reference laboratory for confirmation. </p><p></p><p class="bulletIndent1">Chromogenic STEC agar is a different selective media that can identify <em>E. coli</em> O157:H7 as well as some non-O157:H7 STEC isolates, but it may not be as sensitive for certain non-O157:H7 STEC as antigen immunoassay following broth culture [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shiga toxin enzyme immunoassay (EIA) following incubation in broth culture</strong> – EIAs can detect <em>E. coli</em> O157:H7 as well as non-O157:H7 STEC but fail to detect approximately 10 to 15 percent of <em>E. coli</em> O157:H7 that are detected on agar plating [<a href="#rid34">34-40</a>]. Thus, Shiga toxin EIA testing can be used in addition to, but never in lieu of, selective culture or nucleic acid amplification testing. Antigen testing can theoretically differentiate between Shiga toxins 1 and 2 but some kits do not report the specific toxin(s) present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular testing </strong>– Multiplex molecular panels that include nucleic acid amplification tests (NAATs) that detect the genes for Shiga toxins 1 and 2 are increasingly available and can deliver results within several hours [<a href="#rid41">41</a>]. Molecular detection of a Shiga toxin gene on a specimen from a patient with painful or bloody diarrhea or on a broth culture of the stool can be rapidly diagnostic of an STEC infection, with some caveats:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Specimens should still be submitted for selective culture if a Shiga toxin gene is identified by NAAT. Pathogen isolation is critically important for epidemiologic analysis and outbreak tracing [<a href="#rid42">42,43</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Molecular tests can distinguish between genes encoding Shiga toxins 1 and 2; however, these details are often not reported. If the molecular test result states that STEC is detected, details on toxin type should be requested from the microbiology laboratory. However, the ability to provide this information to the clinician might be limited by the test platform used and laboratory policy. Many NAATs can identify the presence of <em>E. coli</em> O157:H7 by amplification of a gene encoding part of the O157 lipopolysaccharide O-side chain. If this target is identified, it may be assumed that the patient is infected with a high-risk STEC. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In situations other than acute diarrhea (eg, persistent or chronic diarrhea), the clinical relevance of a positive STEC NAAT is uncertain and usually does not warrant specific clinical action, especially if the diarrhea is nonbloody.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If NAAT (or another diagnostic) detects another enteric pathogen (eg, <em>C. difficile</em>,<em> Campylobacter</em>,<em> Salmonella</em>, or <em>Shigella</em>) in addition to a high-risk STEC, we defer antibiotic treatment because of the risk of HUS (see <a class="local">'Antibiotics'</a> below). North American non-O157:H7 STEC possess a gene encoding Shiga toxin 2, which again emphasizes the role of Shiga toxin genotyping in clinical decision-making. Multiple enteric infections are more likely in patients with non-O157:H7 STEC infections than with <em>E. coli </em>O157:H7 infections.</p><p></p><p>Providers are highly reliant on accurate microbiology to manage patients with STEC infections, because the history, physical examination, and common laboratory tests cannot distinguish patients infected with <em>E. coli</em> O157:H7 from those infected with other bacterial enteric pathogens [<a href="#rid14">14</a>]. In our experience, the availability of reliable diagnostic microbiology results early in illness is strongly associated with favorable clinical outcomes in <em>E. coli</em> O157:H7 infections [<a href="#rid44">44</a>]. </p><p>We thus encourage microbiology laboratories to set up cultures throughout the day and night, every day. This practice has been in place in our institution for over a decade and results in return of STEC testing results in 24 hours [<a href="#rid14">14</a>], a considerably shorter interval than reported in centers that have not yet adopted such policies [<a href="#rid22">22</a>]. We also encourage microbiology laboratories to alert clinicians to presumptive positive testing for STEC while awaiting confirmatory testing. </p><p>The spectrum of data that might be provided to the physician during the course of an STEC infection and our recommendations on management when this information becomes available are illustrated in the figure  (<a class="graphic graphic_figure graphicRef121336" href="/z/d/graphic/121336.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H2614314745"><span class="h3">Diagnostic challenges</span><span class="headingEndMark"> — </span>Many nonculture diagnostic tests fail to specify which Shiga toxin is present. In such cases it is helpful to consider the context for bacterial stool culture. If a nondifferentiated toxin result is generated in the setting of bloody diarrhea  (<a class="graphic graphic_figure graphicRef121336" href="/z/d/graphic/121336.html" rel="external">figure 2</a>), the possibility that the infection is caused by a high-risk STEC is substantial. However, in the setting of nonbloody diarrhea, the likelihood that a high-risk STEC is present is lower but not nil. </p><p>The presence or absence of<em> E. coli</em> O157:H7 in the specimen is another way to assess risk. Independent of toxin genotype reported,<em> E. coli</em> O157:H7 is a high-risk STEC. If this serotype has been excluded, the likelihood of high-risk STEC is diminished. The value of testing for<em> E. coli</em> O157:H7 is directly proportional to the likelihood that this serotype is the predominant Shiga toxin 2-producing<em> E. coli</em>. In any ambiguous scenario, options for pending and subsequent testing should be reviewed to optimize management, because Shiga toxin genotype is an important determinant of outcome. </p><p>Another diagnostic challenge is that nucleic acid amplification diagnostics are not approved for swab specimens. </p><p class="headingAnchor" id="H3688384869"><span class="h3">Evaluation for other enteric pathogens</span><span class="headingEndMark"> — </span>Stool or rectal swab specimens should also be evaluated for non-STEC bacterial pathogens that cause bloody diarrhea. In resource-rich settings, we discourage testing for pathogens that do not cause bloody diarrhea (such as viruses and parasites). </p><p>If a multiplex panel identifies a nonbacterial pathogen in the setting of acute bloody diarrhea, we generally do not act on this result; an exception is detection of <em>Entamoeba histolytica </em>in an at-risk patient; however, in North America, such infections are relatively rare. </p><p>We do not recommend testing for <em>Clostridioides</em> <em>difficile</em>, because this infection rarely presents as suddenly as do STEC infections. In addition, fulminant <em>C. difficile </em>colitis is particularly unusual in previously healthy children, and many children and adults excrete <em>C. difficile</em> without symptoms [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H2325923639"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of acute bloody diarrhea predominantly includes other bacterial pathogens, which are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2689.html" rel="external">"Causes of acute infectious diarrhea and other foodborne illnesses in resource-abundant settings", section on 'Inflammatory diarrhea'</a>.)</p><p>Assessing these and other causes of acute diarrhea in children and adults is presented separately. (See  <a class="medical medical_review" href="/z/d/html/6456.html" rel="external">"Diagnostic approach to diarrhea in children in resource-abundant settings", section on 'Acute diarrhea (typical duration &lt;5 days)'</a> and  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H1820841561"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2578854672"><span class="h2">Objectives</span><span class="headingEndMark"> — </span>There are no specific treatments for STEC infections. Therefore, our approach to managing high-risk STEC<em> </em>(ie, <em>E. coli</em> O157:H7 and non-O157 STEC that contain a gene encoding Shiga toxin 2) infections focuses on practices that lower the likelihood of hemolytic uremic syndrome (HUS), particularly anuric HUS. Because of the serious nature of HUS, we apply this approach to patients with suspected, as well as confirmed, infections caused by high-risk STEC  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>). (See <a class="local">'Clinical suspicion'</a> above.)</p><p>We encourage the same approach to management in both children and adults. However, this approach may be less valuable for adults because, compared with children, adults are less likely to be infected with STEC and the rate of HUS in culture-confirmed high-risk STEC infections is lower [<a href="#rid46">46</a>]. However, STEC infections in adults might have higher rates of HUS than previously appreciated, as demonstrated in one North American outbreak, in which the HUS rate exceeded 10 percent in a mostly adult cohort [<a href="#rid21">21</a>].</p><p>Timely and accurate microbiologic testing is also essential for appropriate management, as discussed above. Clear ongoing communication with the microbiology laboratory is a key component of care, although the clinician should be aware of potential difficulties with determining Shiga toxin genotype in a timely manner. (See <a class="local">'Microbiologic diagnosis'</a> above.)</p><p class="headingAnchor" id="H799040960"><span class="h2">Site of care</span><span class="headingEndMark"> — </span>Hospitalization of patients with suspected or confirmed high-risk STEC infection permits aggressive intravenous (IV) fluid management and daily reassessment, which are the fundamental components of management, as detailed in the following sections. Hospitalizing infected patients can also lower the rate of secondary infection in the community [<a href="#rid47">47</a>]. However, in some situations, these patients may be sufficiently stable to be treated as outpatients, as discussed below. </p><p>STEC infections are relatively rare compared with the rate of gastroenteritis caused by other pathogens, and the approach to management of STEC infections differs considerably. Thus, if possible, we encourage admission of patients with confirmed or suspected STEC infection to specific nursing units and care teams to maximize experience and offer optimized center expertise. Partnership with the diagnostic microbiologic laboratory is also a major element of caring for these patients. </p><p class="headingAnchor" id="H2682005608"><span class="h2">Fluid management</span></p><p class="headingAnchor" id="H1722785214"><span class="h3">Aggressive IV volume expansion</span><span class="headingEndMark"> — </span>For patients with suspected or confirmed high-risk STEC infection, we favor early and aggressive IV volume expansion with isotonic crystalloid. In well-hydrated children who can be reassessed daily with physical examinations and laboratory testing (CBC, electrolytes, creatinine), and who have received IV volume expansion on presentation, outpatient management may be reasonable, especially if the patient is not vomiting. </p><p>The rationale for aggressive volume expansion is based on several lines of evidence. In a meta-analysis of observational studies of children with STEC- or diarrhea-associated HUS, apparent volume depletion was associated with mortality, and IV fluid administration was associated with a decreased risk of renal replacement therapy (odds ratio [OR] 0.26, 95% CI 0.11-0.60) [<a href="#rid48">48</a>]. In two prospective cohort studies of children with HUS, pre-HUS volume expansion was associated with lower rates of anuria [<a href="#rid44">44,49</a>]. IV volume expansion has been proposed at initial presentation per community protocol (ie, before HUS ensues) [<a href="#rid50">50,51</a>] and given to children with established HUS [<a href="#rid52">52,53</a>]. </p><p>A peripheral IV catheter is usually sufficient for volume management; in patients who develop peripheral edema, a peripherally inserted central catheter can forestall challenges with access.</p><p>It is uncertain whether IV volume expansion early in illness is associated with reduced frequency of HUS following STEC infections or merely reduces the rate of anuria, which almost always occurs by day 10 of illness [<a href="#rid49">49</a>]. Nevertheless, anuric HUS is categorically worse than nonanuric HUS, so averting anuria has merit even if HUS does develop [<a href="#rid54">54-66</a>]. In one study of children with STEC infection who were evaluated in pediatric emergency departments in North America, those who developed HUS (which occurred at a median of three days after presentation) had higher hematocrits and lower serum sodium concentrations at initial presentation than those who did not [<a href="#rid25">25</a>]. This finding reinforces the value of early recognition of infection and volume expansion, because relative hemoconcentration and hyponatremia are potentially manageable risk factors. </p><p>While observational data suggest that volume expansion early in illness may be associated with better outcomes if HUS occurs, a randomized controlled trial of IV volume expansion would provide the most convincing evidence of the efficacy and safety of this strategy. </p><p class="headingAnchor" id="H3911089423"><span class="h3">Fluid type and content</span><span class="headingEndMark"> — </span>We use isotonic crystalloid (ie, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or a balanced salt solution such as <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">Lactated Ringer</a> solution) rather than hypotonic fluids because the goal of parenteral volume expansion is to preserve renal blood flow, which is better achieved with isotonic fluids. Hyponatremia at the time of HUS diagnosis is associated with worse outcomes, additionally justifying isotonic volume expansion [<a href="#rid67">67</a>]. Except for boluses with 0.9 percent saline or a balanced salt solution, we use fluids containing 5 percent dextrose.</p><p>Vigorous volume expansion using crystalloid in which chloride is the exclusive anion (ie, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) can contribute to iatrogenic hyperchloremic metabolic acidosis. While we generally prefer balanced salt solutions (eg, Lactated Ringers) for volume expansion, such formulations contain sodium at concentrations that are considerably less than the 154 mEq/L concentration of sodium in normal saline. So, if the serum sodium concentration is below normal, we infuse normal saline. Similarly, balanced salt solutions contain &lt;5 mEq/L of potassium, considerably less than what is generally added to normal saline (20 or more mEq/L). This can be remedied by either infusing <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> from a separate bag and collaborating with a pharmacist to increase the potassium concentration or using normal saline with added potassium.</p><p>We monitor serum electrolytes at least daily. Even though STEC-associated HUS is characterized by brisk hemolysis and an imminent risk of renal insufficiency, we inexplicably observe hypokalemia more frequently than hyperkalemia. We adjust the crystalloid depending on the serum sodium concentration. If the serum sodium concentration falls below the lower limits of normal, we revert to normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> if the patient is receiving a balanced salt solution. </p><p class="headingAnchor" id="H223575475"><span class="h3">Rate of administration</span><span class="headingEndMark"> — </span>For patients with suspected or confirmed high-risk STEC infection, we initiate and maintain generous IV volume expansion with isotonic crystalloid. In children, we start with a bolus of at least 20 mL/kg of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and administer 1.5 to 2 times maintenance volume. In adults, we administer aggressive isotonic volume expansion, but the volume administered might be tempered by other clinical considerations, especially if patients have cardiopulmonary conditions that might be exacerbated by fluid administration. </p><p>Our target goal for IV fluid administration is reduction of the hemoglobin concentration. There are multiple studies that demonstrate that the hemoglobin concentration at the time of diagnosis of HUS is directly correlated with HUS severity (ie, relatively elevated hemoglobin concentration reflects a more severe course, including anuria, need for renal replacement therapy, and extra-intestinal complications) [<a href="#rid23">23,52,54,67-72</a>]. To guide hemodilution, we obtain a complete blood count (CBC) every 8 to 12 hours early in illness to monitor the effectiveness of the volume expansion. (See <a class="local">'Daily monitoring'</a> below.) </p><p>The aggressiveness of our attempts to hemodilute patients depends on several factors, including the degree of hemoconcentration, day of illness, and effect of attempts to lower the hemoglobin. Examples of patients in whom we suggest especially vigorous volume expansion include:</p><p class="bulletIndent1"><span class="glyph">●</span>A patient with a hemoglobin of 17 g/dL and a normal platelet count on the third day of diarrhea. For such a patient, we aim for a hemoglobin concentration of 13 g/dL within 24 hours, and even lower 24 hours after that.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient on day 4 of illness with a hemoglobin concentration of 12 g/dL that remains constant or increases over 24 hours despite aggressive volume expansion. Such a situation is concerning for early capillary leakage.</p><p></p><p>Assiduous monitoring of cardiopulmonary status is important in adults, especially in people with pre-existing heart and lung conditions. Assessment of the pulse and respiratory rate and chest auscultation should be performed prior to fluid boluses in patients of all ages.</p><p>If there is any question of diminished urine output or lack of hemoglobin dilution, we also repeat boluses of either normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or balanced salt solution (10 to 20 mL/kg) if the patient does not have signs of central volume overload. Peripheral edema should be expected and should not prompt fluid restriction in the absence of central volume overload. </p><p>The evolution from STEC infection into HUS follows a highly patterned sequence of events  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>), with a decrease in platelets preceding the drop in hemoglobin from hemolysis. Therefore, the day of illness and the trend in the platelet count can be used to determine if a decreased hemoglobin reflects adequate volume expansion versus early hemolysis. A falling hemoglobin concentration accompanied by a slightly falling or stable platelet count on or before day 4 of illness usually reflects desired hemodilution from volume expansion. However, a hemoglobin concentration of 12 g/dL on day 6 of illness in the setting of a platelet count &lt;100,000/microL and normal serum creatinine concentration probably reflects relative hemoconcentration, since hemolysis has likely already started, and the hemoglobin level would have been expected to be in the 8 to 10 g/dL range. In this latter situation, we attempt vigorous volume expansion but also carefully monitor the patient, as azotemia might ensue very quickly. As noted above, relatively elevated hemoglobin at the point in illness when HUS is diagnosed is a poor prognostic sign [<a href="#rid23">23,52,54,67-72</a>].</p><p>At all points in illness, volume contraction in patients infected with STEC cannot simply be attributed to fluid loss from diarrhea (STEC diarrhea is not voluminous). Capillary leakage can occur, often in advance of azotemia. </p><p>Fluid management in patients with HUS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Fluid and electrolyte management'</a>.)</p><p class="headingAnchor" id="H1607699026"><span class="h2">Daily monitoring</span><span class="headingEndMark"> — </span>Because infections with high-risk STEC evolve day by day and management is guided by the phase of illness, daily reassessment is critical [<a href="#rid26">26</a>]. Clinical assessment includes evaluation of symptoms (eg, whether the diarrhea is improved, and abdominal pain has decreased), volume status, and urine output.</p><p>We perform a CBC every 8 to 12 hours during the first 24 hours of IV fluid administration to confirm that volume expansion is achieving its goal of therapeutic hemodilution (see <a class="local">'Rate of administration'</a> above); thereafter, we check this value at least daily. We also check electrolytes and creatinine daily, with more frequent checks if concerning abnormalities develop. Serum albumin concentrations are sometimes useful later in illness, especially if there is peripheral edema, as albumin infusions can be helpful to expand intravascular volume and reduce edema. (See <a class="local">'Hypoalbuminemia'</a> below.)</p><p>Daily monitoring is also important to identify HUS early, if this outcome develops. We strongly endorse a stringent, age-focused definition for HUS diagnosis that is based on the simultaneous occurrence of [<a href="#rid73">73,74</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Hematocrit &lt;30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;150,000/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine concentration greater than the upper limit of normal for the patient's age</p><p></p><p>Other UpToDate authors diagnose STEC-associated HUS more generally based on the triad of microangiopathic hemolytic anemia with fragmented red blood cells, thrombocytopenia, and acute kidney injury (as defined by a decrease in the estimated glomerular filtration rate). (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H536939260"><span class="h2">Timing of fluid discontinuation and discharge</span><span class="headingEndMark"> — </span>For patients with confirmed infection caused by a high-risk STEC, discontinuation of IV fluids depends chiefly on the stage of the illness and the platelet count as well as clinical improvement  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>) (see <a class="local">'Daily monitoring'</a> above). We consider the first day of illness to be the first day of diarrhea (not the first day of bloody diarrhea)  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Days 1 through 4 of illness (early phase)</strong> – We generally continue IV fluids through the first four days of illness, as we do not have enough experience with trends in the clinical trajectory during this time to confidently halt volume expansion. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Days 5 through 9 of illness (middle phase) </strong>– We discontinue IV fluids and discharge the patient if the platelets have increased by at least 5 percent compared with the day prior and the patient's clinical condition has improved (eg, diarrhea and abdominal pain have considerably improved). We check a CBC the following day. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 10 or later of illness</strong> <strong>(late phase) </strong>– We discontinue IV fluids and discharge the patient if the platelets have not decreased by over 5 percent compared with the day prior and the patient's clinical condition has improved. We check a CBC the following day. </p><p></p><p>A decrease in platelets is often the first laboratory manifestation of HUS. Based on our clinical experience, rising platelet levels in the middle or late phases of illness suggest that the risk for HUS has passed. We have used the 5 percent threshold to manage many patients without adverse event, but it has not been systematically evaluated. </p><p>The post-discharge CBC is performed to ensure there is no decrease in the platelet count reflecting late deterioration. This is unusual, but if it does occur, we typically readmit patients for an additional day or two of IV fluids. We also obtain a repeat rectal swab or stool culture prior to discharge in patients who may need to document a negative culture prior to returning to daycare, school, or work. (See <a class="local">'Return to school or work'</a> below.)</p><p>For patients who were managed with volume expansion because of suspected STEC but had negative microbiologic testing and are clinically improving, IV fluid can be discontinued.</p><p class="headingAnchor" id="H264589781"><span class="h2">Avoid potentially harmful interventions</span></p><p class="headingAnchor" id="H1276448656"><span class="h3">Antibiotics</span><span class="headingEndMark"> — </span>We recommend against treating confirmed or suspected STEC infections (either <em>E. coli</em> O157:H7 or non-O157:H7) with antibiotics [<a href="#rid75">75</a>]. If an STEC is identified in patients in whom antibiotic therapy was initiated empirically, we discontinue it. </p><p>This recommendation is based on the association between antibiotics and the development of HUS in patients with STEC infection. The risk was illustrated by a meta-analysis of mainly observational studies that included over 1800 patients with STEC infection [<a href="#rid76">76</a>]. When all studies were pooled, there was a nonsignificant trend toward a higher risk of HUS with antibiotic use (pooled OR 1.33, 95% CI 0.89-1.99). However, among studies that were deemed to have low risk of bias and that employed a stringent definition of HUS, the association was stronger (pooled OR 2.24, 95% CI 1.45-3.36) [<a href="#rid74">74</a>]. One of the studies included was a prospective study of 259 children &lt;10 years of age infected with <em>E. coli</em> O157:H7 [<a href="#rid77">77</a>]. HUS occurred more frequently in the 25 children who received antibiotics, which included <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, beta-lactams, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (36 compared with 12 percent in those who did not receive antibiotics). After adjusting for other variables, the absolute antibiotic-attributable risk increase for HUS incidence was 25 percent, corresponding to one case of HUS for every four children treated with antibiotics. Data in adults are sparser; in three studies among adults that were included in the meta-analysis discussed above and were considered high quality, antibiotics administered early in STEC infection were associated with subsequent development of HUS [<a href="#rid1">1,76,78,79</a>]. </p><p>In contrast to these data, we are unaware of any study that has convincingly demonstrated that antibiotics reduce the risk of developing HUS in people of any age who are infected with a high-risk STEC.</p><p>Antibiotics have not been shown to reduce symptoms or other complications associated with STEC infections [<a href="#rid80">80</a>]. </p><p class="headingAnchor" id="H2937622846"><span class="h3">Other medications</span><span class="headingEndMark"> — </span>We avoid several nonantibiotic medications that might be used in acute painful gastroenteritis because of lack of benefit and/or potential harm in patients with STEC infection:</p><p class="bulletIndent1"><span class="glyph">●</span>Antimotility agents (including opioids) – These agents have been associated with a higher risk of HUS and, among those who develop HUS, complicated HUS (eg, with central nervous system dysfunction) [<a href="#rid6">6,70,81</a>]. In one study, they were also associated with prolongation of gastrointestinal symptoms [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal anti-inflammatory drugs (including <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a>) – These agents can diminish renal blood flow and, thus, can theoretically exacerbate ischemic damage to the kidney that likely underlies renal failure in HUS. They are demonstrated to cause renal injury in children with gastroenteritis from all causes [<a href="#rid82">82</a>], and abdominal discomfort is unlikely to respond to these agents. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IV <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> – This serotonin 5-H<sub>3</sub> receptor antagonist can prolong the QT interval. Given that a subset of deaths during HUS are sudden, we believe that it is prudent to avoid this potentially arrhythmogenic agent [<a href="#rid83">83</a>]. Orally administered ondansetron is safer but, in our experience, rarely stops vomiting associated with STEC infections.</p><p></p><p class="headingAnchor" id="H1127972958"><span class="h2">Other management issues</span></p><p class="headingAnchor" id="H3754766202"><span class="h3">Pain control</span><span class="headingEndMark"> — </span>Given that abdominal pain may be partly attributable to intestinal ischemia, management consists of careful fluid management as outlined above. (See <a class="local">'Fluid management'</a> above.)</p><p>We avoid opioids (which may adversely affect peristalsis) and nonsteroidal anti-inflammatory drugs (which may exacerbate renal injury). (See <a class="local">'Avoid potentially harmful interventions'</a> above.)</p><p class="headingAnchor" id="H1105005704"><span class="h3">Hypoalbuminemia</span><span class="headingEndMark"> — </span>Many STEC-infected patients are hypoalbuminemic. If the patient has peripheral edema or diminishing urine output and the serum albumin concentration is &lt;3 g/dL, we suggest judicious albumin infusions (eg, 0.5 g/kg once, and then repeated several hours later) to draw extracellular fluid into blood vessels and increase circulating blood volume. We do not administer albumin with a diuretic unless there is cardiopulmonary overload.</p><p class="headingAnchor" id="H195204341"><span class="h3">Anemia and thrombocytopenia</span><span class="headingEndMark"> — </span>Occasionally, severe anemia from hemolysis can precede, or occur in the absence of, azotemia (ie, before criteria for HUS have been met or even in situations in which HUS does not develop). If the patient is neither tachycardic nor hypoxemic, we attempt to delay transfusion. Almost all patients with STEC-related HUS ultimately require at least one red blood cell transfusion, but delaying this intervention seems prudent because the added pigment load from continuing hemolysis might be nephrotoxic. We also monitor for hypertension during or following transfusion.</p><p>Patients infected with a high-risk STEC can also develop quite severe thrombocytopenia before, or even in the absence of, azotemia. We do not use platelet transfusions unless there is severe bleeding, which is unusual. As HUS is a thrombotic injury, clinically consequential hemorrhagic complications are rare, and platelet infusions theoretically could exacerbate the thrombotic state. </p><p class="headingAnchor" id="H160126234"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H2655942725"><span class="h2">Exposed asymptomatic individuals</span><span class="headingEndMark"> — </span>We advise individuals exposed to an outbreak source and household contacts of infected patients to monitor symptoms and seek medical care if they develop diarrhea. Otherwise, we do not recommend interventions (ie, volume expansion) in the absence of symptoms. There are no data demonstrating a benefit of antibiotics or other interventions in preventing infection or other complications in an exposed but presymptomatic individual. </p><p class="headingAnchor" id="H1865934318"><span class="h2">Late presentation</span><span class="headingEndMark"> — </span>Late presentation of STEC infection (ie, at day 9 or later, in the absence of hemolytic uremic syndrome [HUS]) is a fairly uncommon situation  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>). If patients are diagnosed with STEC in an apparent convalescent phase (ie, on or after day 10 of illness), hospital admission and intravenous (IV) fluid administration are not necessary if there is no evidence of HUS. We do, however, suggest that a complete blood count (CBC), blood urea nitrogen (BUN), and creatinine be checked on presentation and again the following day in such patients. </p><p class="headingAnchor" id="H653731334"><span class="h2">Fever or secondary infection</span><span class="headingEndMark"> — </span>Many patients with STEC infection report fever prior to seeking care, but almost all are afebrile on presentation. Documentation of a fever following presentation should prompt workup for other infections; for example, we obtain blood cultures and chest radiograph. </p><p>For patients with STEC infection who have not developed HUS, the clinician should be judicious about seeking other infections and ensure that a concurrent infection truly warrants antibiotic therapy because of the association between antibiotics and HUS (see <a class="local">'Antibiotics'</a> above). It may not be necessary to treat certain coincident bacterial infections, such as otitis media, another co-detected bacterial enteric infection, or group A streptococcal pharyngitis. Although rare, STEC-infected patients can have serious simultaneous infections, such as invasive pneumococcal [<a href="#rid49">49</a>] or <em>Clostridium septicum</em> infection [<a href="#rid84">84-87</a>]. In these situations, antibiotics are clearly warranted, and it is advisable to draw sufficient blood for anaerobic blood cultures. </p><p>Once a patient has developed HUS, and especially if they have developed anuric HUS, antibiotics should not be withheld if there is good justification for their use. However, we avoid <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> in such cases because HUS results in a pigment load that can lead to biliary stones [<a href="#rid88">88</a>], and ceftriaxone may exacerbate this process.</p><p class="headingAnchor" id="H906506112"><span class="h2">Rapidly improved symptoms</span><span class="headingEndMark"> — </span>Patients whose bloody diarrhea resolves rapidly (eg, within a few hours) are not at risk of having an STEC infection; bacterial diarrhea rarely improves so rapidly. If such patients had been admitted for management, it is reasonable to discharge them after a few hours of observation. </p><p class="headingAnchor" id="H3101054170"><span class="h2">HUS in older adults</span><span class="headingEndMark"> — </span>Among older adults who develop hemolytic uremic syndrome (HUS), myocardial ischemia, acute congestive heart failure, and other cardiac complications have been reported [<a href="#rid89">89</a>]. We encourage vigilance in such patients for any signs of cardiac deterioration and to have a low threshold for obtaining a troponin and echocardiogram if indicated. </p><p>The approach to suspected heart failure is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H1003781007"><span class="h2">Infants</span><span class="headingEndMark"> — </span>In North America, STEC infections in infants are quite rare. We therefore do not apply our fluid protocols in children younger than nine months of age prior to microbiologic confirmation of an STEC infection. There is some overlap in the clinical characteristics of STEC infections in children and intussusception (and some children can have both). (See <a class="local">'Other'</a> above.)</p><p class="headingAnchor" id="H2676063849"><span class="h1">INFECTION CONTROL MEASURES</span></p><p class="headingAnchor" id="H1852839191"><span class="h2">Inpatient precautions</span><span class="headingEndMark"> — </span>Hospitalized patients with STEC infections should be placed on contact precautions to reduce person-to-person transmission [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p class="headingAnchor" id="H4178043054"><span class="h2">Public health notification</span><span class="headingEndMark"> — </span>The local public health authorities should be notified of any patient diagnosed with STEC or hemolytic uremic syndrome (HUS). This is important for outbreak tracking and source identification. In the United States, the relevant authority is generally the public health department in the county in which the patient resides. The clinical microbiology laboratory or hospital infection control team can provide guidance regarding contact details. </p><p>We discourage providers from attempting to gather epidemiologic data themselves and encourage them to defer epidemiologic investigations to the public health authorities; case questionnaires used by health departments are quite detailed and are designed to gain maximal information without prompting biased responses.</p><p class="headingAnchor" id="H2038686934"><span class="h2">Identifying sick contacts</span><span class="headingEndMark"> — </span>Any acutely ill family members of patients with STEC infection should be advised to seek medical care; their clinician should be alerted to exposure to a patient with STEC infection. </p><p class="headingAnchor" id="H1323172540"><span class="h2">Return to school or work</span><span class="headingEndMark"> — </span>Local health jurisdictions have varying policies regarding exclusion from daycare and food handling jobs to prevent post-infectious transmissions of these pathogens. Physicians should defer to their policies. </p><p>A negative stool culture is often requested prior to return to daycare, school, or other sensitive settings (eg, occupation with food preparation). For children, we typically obtain a stool culture prior to discharge from the hospital, as this is more convenient than submitting an outpatient specimen. </p><p class="headingAnchor" id="H4130638967"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109942.html" rel="external">"Society guideline links: Acute diarrhea in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110029.html" rel="external">"Society guideline links: Acute diarrhea in children"</a>.)</p><p class="headingAnchor" id="H348071870"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86006.html" rel="external">"Patient education: E. coli diarrhea (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1340191318"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Shiga toxin-producing <em>Escherichia coli</em> (STEC) fall into two clinically relevant categories: those that contain a gene encoding Shiga toxin 2 (with or without a gene encoding Shiga toxin 1) and those that do not (ie, their only Shiga toxin gene encodes Shiga toxin 1)  (<a class="graphic graphic_table graphicRef120224" href="/z/d/graphic/120224.html" rel="external">table 1</a>). Shiga toxin 2 production is associated with serious infection characterized by bloody diarrhea and a risk for hemolytic uremic syndrome (HUS). Almost all <em>E. coli</em> O157:H7 contain a gene encoding Shiga toxin 2; only a subset of non-O157:H7 <em>E. coli</em> contain a gene encoding Shiga toxin 2. We use the term "high-risk STEC" to collectively refer to these Shiga toxin 2-producing pathogens. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The course of infection with high-risk STEC follows a highly patterned sequence of events  (<a class="graphic graphic_figure graphicRef75352" href="/z/d/graphic/75352.html" rel="external">figure 1</a>). The first day of diarrhea is considered the first day of illness. Diarrhea is initially nonbloody, but in most patients, becomes visibly bloody one to three days later. Abdominal pain is common; fever at presentation is uncommon, although many patients report fevers early in illness (ie, before they present for care). HUS, if it occurs, is usually established between days 5 and 13 of illness. (See <a class="local">'Clinical features'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical suspicion</strong> – A high-risk STEC infection should be suspected in all patients of all ages with acute bloody diarrhea and abdominal tenderness  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>). It should also be suspected in individuals with diarrhea and prior contact with a known STEC patient and in individuals with HUS, even if they do not have diarrhea. Fever does not rule out the possibility of an STEC infection. (See <a class="local">'Clinical suspicion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microbiologic diagnosis</strong> – Rapid, accurate, and complete diagnostic microbiology is critical for detecting STEC infections. Unless the patient immediately produces a stool specimen, we encourage obtaining and submitting rectal swab specimens to detect STEC. The diagnosis of a high-risk STEC infection is made in a patient with acute diarrhea when <em>E. coli</em> O157:H7 is isolated on selective culture or when Shiga toxin 2 (or a gene encoding this toxin) is detected. Although many molecular tests can distinguish between Shiga toxins 1 and 2, this detail is not necessarily reported and must be specifically requested. (See <a class="local">'Microbiologic diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Our approach to managing suspected or confirmed high-risk STEC infections focuses on practices that lower the likelihood of HUS, particularly anuric HUS. In general we favor hospital admission for such patients to permit aggressive intravenous (IV) fluid management and daily reassessment  (<a class="graphic graphic_algorithm graphicRef121527" href="/z/d/graphic/121527.html" rel="external">algorithm 1</a>); however, outpatient monitoring may be appropriate for patients who are well hydrated, not vomiting, have received a bolus of isotonic crystalloid, and can be reassessed daily with repeat laboratory tests (CBC, chemistries). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid management</strong> – For patients with suspected or confirmed high-risk STEC infection, we suggest early IV volume expansion with isotonic crystalloid with a goal of reducing the hemoglobin concentration (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally start with a bolus of at least 20 mL/kg of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and administer up to twice maintenance volume. Discontinuation of IV fluids depends on the day and stage of the illness, the trend in the platelet count, and the clinical condition based on daily monitoring. (See <a class="local">'Fluid management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avoiding harmful interventions</strong> – We recommend <strong>not</strong> treating confirmed high-risk STEC infections with antibiotics (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We also do not use empiric antibiotics in suspected STEC infections, pending microbiologic testing. If STEC is identified in patients in whom antibiotic therapy was initiated empirically, we discontinue it. Antibiotics do not reduce symptoms or complications of STEC infection and have been associated with development of HUS. (See <a class="local">'Antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control</strong> – Hospitalized patients with STEC infections should be placed on contact precautions to reduce person-to-person transmission. Local public health authorities should be notified. A negative stool culture is often requested prior to return to daycare, school, or other sensitive settings (eg, occupation with food preparation). (See <a class="local">'Infection control measures'</a> above.)</p><p></p><p class="headingAnchor" id="H3997428130"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sarah Greene, MD, who contributed to a revision of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cadwgan AM, Laing RB, Dargie L, et al. Three years experience of adults admitted to hospital in north-east Scotland with E. coli O157. Scott Med J 2002; 47:112.</a></li><li><a class="nounderline abstract_t">Jelacic S, Wobbe CL, Boster DR, et al. ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections. J Infect Dis 2002; 185:214.</a></li><li><a class="nounderline abstract_t">Ostroff SM, Tarr PI, Neill MA, et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 1989; 160:994.</a></li><li><a class="nounderline abstract_t">Ardissino G, Possenti I, Vignati C, et al. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network. Pediatr Nephrol 2020; 35:1997.</a></li><li><a class="nounderline abstract_t">Tarr GAM, Stokowski T, Shringi S, et al. Contribution and Interaction of Shiga Toxin Genes to Escherichia coli O157:H7 Virulence. Toxins (Basel) 2019; 11.</a></li><li><a class="nounderline abstract_t">Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12.</a></li><li><a class="nounderline abstract_t">Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.</a></li><li><a class="nounderline abstract_t">Ostroff SM, Kobayashi JM, Lewis JH. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 1989; 262:355.</a></li><li><a class="nounderline abstract_t">Brandt JR, Fouser LS, Watkins SL, et al. Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125:519.</a></li><li><a class="nounderline abstract_t">Miceli S, Jure MA, de Saab OA, et al. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina. Jpn J Infect Dis 1999; 52:33.</a></li><li><a class="nounderline abstract_t">Grisaru S, Berenger B, Freedman S. Case 19-2018: A 15-Year-Old Girl with Acute Kidney Injury. N Engl J Med 2018; 379:e34.</a></li><li><a class="nounderline abstract_t">Wang X, Taylor M, Hoang L, et al. Comparison of clinical and epidemiological features of Shiga toxin-producing Escherichia coli O157 and non-O157 infections in British Columbia, 2009 to 2011. Can J Infect Dis Med Microbiol 2013; 24:e102.</a></li><li><a class="nounderline abstract_t">Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.</a></li><li><a class="nounderline abstract_t">McKee RS, Tarr PI, Dietzen DJ, et al. Clinical and Laboratory Predictors of Shiga Toxin-Producing Escherichia coli Infection in Children With Bloody Diarrhea. J Pediatric Infect Dis Soc 2018; 7:e116.</a></li><li><a class="nounderline abstract_t">Klein EJ, Stapp JR, Clausen CR, et al. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J Pediatr 2002; 141:172.</a></li><li><a class="nounderline abstract_t">Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346:23.</a></li><li><a class="nounderline abstract_t">Smith JM, Jones F, Ciol MA, et al. Platelet-activating factor and Escherichia coliO157:H7 infections. Pediatr Nephrol 2002; 17:1047.</a></li><li><a class="nounderline abstract_t">Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49:653.</a></li><li><a class="nounderline abstract_t">Petruzziello-Pellegrini TN, Yuen DA, Page AV, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 2012; 122:759.</a></li><li><a class="nounderline abstract_t">Page AV, Tarr PI, Watkins SL, et al. Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome. J Infect Dis 2013; 208:929.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Multistate Outbreak of E. coli O157:H7 Infections Linked to Romaine Lettuce (Final Update). June 28, 2018. https://www.cdc.gov/ecoli/2018/o157h7-04-18/index.html (Accessed on April 01, 2019).</li><li><a class="nounderline abstract_t">Freedman SB, Eltorki M, Chui L, et al. Province-Wide Review of Pediatric Shiga Toxin-Producing Escherichia coli Case Management. J Pediatr 2017; 180:184.</a></li><li><a class="nounderline abstract_t">Mody RK, Gu W, Griffin PM, et al. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 2015; 166:1022.</a></li><li><a class="nounderline abstract_t">Cha PI, Gurland B, Forrester JD. First Reported Case of Intussusception Caused by Escherichia coli O157:H7 in an Adult: Literature Review and Case Report. Surg Infect (Larchmt) 2019; 20:95.</a></li><li><a class="nounderline abstract_t">McKee RS, Schnadower D, Tarr PI, et al. Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children. Clin Infect Dis 2020; 70:1643.</a></li><li><a class="nounderline abstract_t">Davis TK, McKee R, Schnadower D, Tarr PI. Treatment of Shiga toxin-producing Escherichia coli infections. Infect Dis Clin North Am 2013; 27:577.</a></li><li><a class="nounderline abstract_t">Davis TK, Van De Kar NCAJ, Tarr PI. Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives. Microbiol Spectr 2014; 2:EHEC.</a></li><li><a class="nounderline abstract_t">Holtz LR, Neill MA, Tarr PI. Acute bloody diarrhea: a medical emergency for patients of all ages. Gastroenterology 2009; 136:1887.</a></li><li><a class="nounderline abstract_t">Freedman SB, Xie J, Nettel-Aguirre A, et al. Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocked swabs with stool specimens: an outpatient cohort study. Lancet Gastroenterol Hepatol 2017; 2:662.</a></li><li><a class="nounderline abstract_t">Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:813.</a></li><li><a class="nounderline abstract_t">Jean S, Yarbrough ML, Anderson NW, Burnham CA. Culture of Rectal Swab Specimens for Enteric Bacterial Pathogens Decreases Time to Test Result While Preserving Assay Sensitivity Compared to Bulk Fecal Specimens. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 2017; 65:e45.</a></li><li><a class="nounderline abstract_t">Zelyas N, Poon A, Patterson-Fortin L, et al. Assessment of commercial chromogenic solid media for the detection of non-O157 Shiga toxin-producing Escherichia coli (STEC). Diagn Microbiol Infect Dis 2016; 85:302.</a></li><li><a class="nounderline abstract_t">Qin X, Klein EJ, Galanakis E, et al. Real-Time PCR Assay for Detection and Differentiation of Shiga Toxin-Producing Escherichia coli from Clinical Samples. J Clin Microbiol 2015; 53:2148.</a></li><li><a class="nounderline abstract_t">Fey PD, Wickert RS, Rupp ME, et al. Prevalence of non-O157:H7 shiga toxin-producing Escherichia coli in diarrheal stool samples from Nebraska. Emerg Infect Dis 2000; 6:530.</a></li><li><a class="nounderline abstract_t">Church DL, Emshey D, Semeniuk H, et al. Evaluation of BBL CHROMagar O157 versus sorbitol-MacConkey medium for routine detection of Escherichia coli O157 in a centralized regional clinical microbiology laboratory. J Clin Microbiol 2007; 45:3098.</a></li><li><a class="nounderline abstract_t">Carroll KC, Adamson K, Korgenski K, et al. Comparison of a commercial reversed passive latex agglutination assay to an enzyme immunoassay for the detection of Shiga toxin-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2003; 22:689.</a></li><li><a class="nounderline abstract_t">Schindler EI, Sellenriek P, Storch GA, et al. Shiga toxin-producing Escherichia coli: a single-center, 11-year pediatric experience. J Clin Microbiol 2014; 52:3647.</a></li><li><a class="nounderline abstract_t">Denno DM, Shaikh N, Stapp JR, et al. Diarrhea etiology in a pediatric emergency department: a case control study. Clin Infect Dis 2012; 55:897.</a></li><li><a class="nounderline abstract_t">Lockary VM, Hudson RF, Ball CL. Shiga toxin-producing Escherichia coli, Idaho. Emerg Infect Dis 2007; 13:1262.</a></li><li><a class="nounderline abstract_t">Anderson NW, Tarr PI. Multiplex Nucleic Acid Amplification Testing to Diagnose Gut Infections: Challenges, Opportunities, and Result Interpretation. Gastroenterol Clin North Am 2018; 47:793.</a></li><li><a class="nounderline abstract_t">Imdad A, Retzer F, Thomas LS, et al. Impact of Culture-Independent Diagnostic Testing on Recovery of Enteric Bacterial Infections. Clin Infect Dis 2018; 66:1892.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Culture-Independent Diagnostic Tests, 2016. https://www.cdc.gov/foodsafety/challenges/cidt.html (Accessed on October 02, 2018).</li><li><a class="nounderline abstract_t">Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115:e673.</a></li><li><a class="nounderline abstract_t">Pollock NR, Banz A, Chen X, et al. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay. Clin Infect Dis 2019; 68:78.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. MMWR: Summary of Notifiable Infectious Diseases. https://www.cdc.gov/mmwr/mmwr_nd/index.html (Accessed on April 01, 2019).</li><li><a class="nounderline abstract_t">Werber D, Mason BW, Evans MR, Salmon RL. Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis 2008; 46:1189.</a></li><li><a class="nounderline abstract_t">Grisaru S, Xie J, Samuel S, et al. Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis. JAMA Pediatr 2017; 171:68.</a></li><li><a class="nounderline abstract_t">Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165:884.</a></li><li><a class="nounderline abstract_t">Loconsole D, Giordano M, Laforgia N, et al. Case-management protocol for bloody diarrhea as a model to reduce the clinical impact of Shiga toxin-producing Escherichia coli infections. Experience from Southern Italy. Eur J Clin Microbiol Infect Dis 2020; 39:539.</a></li><li><a class="nounderline abstract_t">Bilkis MD, Bonany P. Hydration in hemolytic uremic syndrome. Arch Argent Pediatr 2021; 119:62.</a></li><li><a class="nounderline abstract_t">Ardissino G, Tel F, Possenti I, et al. Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Bonany P, Bilkis MD, Iglesias G, et al. Fluid restriction versus volume expansion in children with diarrhea-associated HUS: a retrospective observational study. Pediatr Nephrol 2021; 36:103.</a></li><li><a class="nounderline abstract_t">Balestracci A, Martin SM, Toledo I, et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 2012; 27:1407.</a></li><li><a class="nounderline abstract_t">Dolislager D, Tune B. The hemolytic-uremic syndrome: spectrum of severity and significance of prodrome. Am J Dis Child 1978; 132:55.</a></li><li><a class="nounderline abstract_t">Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290:1360.</a></li><li><a class="nounderline abstract_t">Gianantonio CA, Vitacco M, Mendilaharzu F, Gallo G. The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up. J Pediatr 1968; 72:757.</a></li><li><a class="nounderline abstract_t">Gianantonio CA, Vitacco M, Mendilaharzu F, et al. The hemolytic-uremic syndrome. Nephron 1973; 11:174.</a></li><li><a class="nounderline abstract_t">Hüseman D, Gellermann J, Vollmer I, et al. Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow. Pediatr Nephrol 1999; 13:672.</a></li><li><a class="nounderline abstract_t">Loirat C. [Post-diarrhea hemolytic-uremic syndrome: clinical aspects]. Arch Pediatr 2001; 8 Suppl 4:776s.</a></li><li><a class="nounderline abstract_t">Mencía Bartolomé S, Martínez de Azagra A, de Vicente Aymat A, et al. [Uremic hemolytic syndrome. Analysis of 43 cases]. An Esp Pediatr 1999; 50:467.</a></li><li><a class="nounderline abstract_t">Mizusawa Y, Pitcher LA, Burke JR, et al. Survey of haemolytic-uraemic syndrome in Queensland 1979-1995. Med J Aust 1996; 165:188.</a></li><li><a class="nounderline abstract_t">Oakes RS, Kirkham JK, Nelson RD, Siegler RL. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008; 23:1303.</a></li><li><a class="nounderline abstract_t">Siegler RL, Pavia AT, Christofferson RD, Milligan MK. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94:35.</a></li><li><a class="nounderline abstract_t">Spizzirri FD, Rahman RC, Bibiloni N, et al. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 1997; 11:156.</a></li><li><a class="nounderline abstract_t">Tönshoff B, Sammet A, Sanden I, et al. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron 1994; 68:63.</a></li><li><a class="nounderline abstract_t">Alconcher LF, Coccia PA, Suarez ADC, et al. Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 2018; 33:1791.</a></li><li><a class="nounderline abstract_t">Balestracci A, Martin SM, Toledo I, et al. Laboratory predictors of acute dialysis in hemolytic uremic syndrome. Pediatr Int 2014; 56:234.</a></li><li><a class="nounderline abstract_t">Ardissino G, Daccò V, Testa S, et al. Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 2015; 30:345.</a></li><li><a class="nounderline abstract_t">Cimolai N, Morrison BJ, Carter JE. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics 1992; 90:616.</a></li><li><a class="nounderline abstract_t">Oakes RS, Siegler RL, McReynolds MA, et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 2006; 117:1656.</a></li><li><a class="nounderline abstract_t">Loos S, Oh J, van de Loo L, et al. Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2021; 36:3777.</a></li><li><a class="nounderline abstract_t">Tarr GAM, Oltean HN, Phipps AI, et al. Case definitions of hemolytic uremic syndrome following Escherichia coli O157:H7 infection vary in validity. Int J Med Microbiol 2018; 308:1121.</a></li><li><a class="nounderline abstract_t">Tarr GAM, Oltean HN, Phipps AI, et al. Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition. Int J Med Microbiol 2018; 308:921.</a></li><li><a class="nounderline abstract_t">Tarr PI, Freedman SB. Why antibiotics should not be used to treat Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 2022; 38:30.</a></li><li><a class="nounderline abstract_t">Freedman SB, Xie J, Neufeld MS, et al. Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis. Clin Infect Dis 2016; 62:1251.</a></li><li><a class="nounderline abstract_t">Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012; 55:33.</a></li><li><a class="nounderline abstract_t">Dundas S, Todd WT, Stewart AI, et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33:923.</a></li><li><a class="nounderline abstract_t">Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505.</a></li><li><a class="nounderline abstract_t">Proulx F, Turgeon JP, Delage G, et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992; 121:299.</a></li><li><a class="nounderline abstract_t">Cimolai N, Carter JE, Morrison BJ, Anderson JD. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990; 116:589.</a></li><li><a class="nounderline abstract_t">Balestracci A, Ezquer M, Elmo ME, et al. Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis. Pediatr Nephrol 2015; 30:1873.</a></li><li><a class="nounderline abstract_t">Robson WL, Leung AK, Montgomery MD. Causes of death in hemolytic uremic syndrome. Child Nephrol Urol 1991; 11:228.</a></li><li><a class="nounderline abstract_t">Barnham M, Weightman N. Clostridium septicum infection and hemolytic uremic syndrome. Emerg Infect Dis 1998; 4:321.</a></li><li><a class="nounderline abstract_t">Martin SE, Allen SD, Faught P, et al. A 2-year-old boy with hemolytic uremic syndrome and pneumocephalus. Brain Pathol 2012; 22:121.</a></li><li><a class="nounderline abstract_t">Williams EJ, Mitchell P, Mitra D, Clark JE. A microbiological hazard of rural living: Clostridium septicum brain abscess in a child with E coli 0157 associated haemolytic uraemic syndrome. BMJ Case Rep 2012; 2012.</a></li><li><a class="nounderline abstract_t">Engen RM, Killien EY, Davis JL, et al. C septicum Complicating Hemolytic Uremic Syndrome: Survival Without Surgical Intervention. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Brandt JR, Joseph MW, Fouser LS, et al. Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Nephrol 1998; 12:222.</a></li><li><a class="nounderline abstract_t">Travert B, Dossier A, Jamme M, et al. Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017. Emerg Infect Dis 2021; 27:1876.</a></li><li class="breakAll">Committee on Infectious Diseases, American Academy of Pediatrics. Section 2: Recommendations for Care of Children in Special Circumstances. In: Red Book: 2018 Report of the Committee on Infectious Diseases, Kimberlin DW, Brady MT, Jackson MA, et al. (Eds), American Academy of Pediatrics, 2018. p.113.</li></ol></div><div id="topicVersionRevision">Topic 2714 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12469565" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Three years experience of adults admitted to hospital in north-east Scotland with E. coli O157.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807695" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2685131" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32734345" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31635282" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Contribution and Interaction of Shiga Toxin Genes to Escherichia coli O157:H7 Virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9200386" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781103" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661870" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7931869" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816611" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30422596" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Case 19-2018: A 15-Year-Old Girl with Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24489568" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of clinical and epidemiological features of Shiga toxin-producing Escherichia coli O157 and non-O157 infections in British Columbia, 2009 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10874060" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617871" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical and Laboratory Predictors of Shiga Toxin-Producing Escherichia coli Infection in Children With Bloody Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12183710" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777999" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478356" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Platelet-activating factor and Escherichia coliO157:H7 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328948" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232208" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801605" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801605" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27745751" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Province-Wide Review of Pediatric Shiga Toxin-Producing Escherichia coli Case Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25661408" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30359547" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : First Reported Case of Intussusception Caused by Escherichia coli O157:H7 in an Adult: Literature Review and Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31125419" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011831" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of Shiga toxin-producing Escherichia coli infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104210" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19457417" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute bloody diarrhea: a medical emergency for patients of all ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28712662" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocked swabs with stool specimens: an outpatient cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169655" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944186" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Culture of Rectal Swab Specimens for Enteric Bacterial Pathogens Decreases Time to Test Result While Preserving Assay Sensitivity Compared to Bulk Fecal Specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053792" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157987" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessment of commercial chromogenic solid media for the detection of non-O157 Shiga toxin-producing Escherichia coli (STEC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25926491" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Real-Time PCR Assay for Detection and Differentiation of Shiga Toxin-Producing Escherichia coli from Clinical Samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10998385" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevalence of non-O157:H7 shiga toxin-producing Escherichia coli in diarrheal stool samples from Nebraska.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634298" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluation of BBL CHROMagar O157 versus sorbitol-MacConkey medium for routine detection of Escherichia coli O157 in a centralized regional clinical microbiology laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574618" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of a commercial reversed passive latex agglutination assay to an enzyme immunoassay for the detection of Shiga toxin-producing Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078916" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Shiga toxin-producing Escherichia coli: a single-center, 11-year pediatric experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22700832" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diarrhea etiology in a pediatric emergency department: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17953111" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Shiga toxin-producing Escherichia coli, Idaho.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337033" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Multiplex Nucleic Acid Amplification Testing to Diagnose Gut Infections: Challenges, Opportunities, and Result Interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29293941" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of Culture-Independent Diagnostic Testing on Recovery of Enteric Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29293941" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of Culture-Independent Diagnostic Testing on Recovery of Enteric Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930195" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788296" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788296" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444854" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893870" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784993" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776873" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Case-management protocol for bloody diarrhea as a model to reduce the clinical impact of Shiga toxin-producing Escherichia coli infections. Experience from Southern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33458983" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hydration in hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644486" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32681274" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fluid restriction versus volume expansion in children with diarrhea-associated HUS: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22476204" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/623065" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The hemolytic-uremic syndrome: spectrum of severity and significance of prodrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966129" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5652602" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4542964" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502125" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11582927" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : [Post-diarrhea hemolytic-uremic syndrome: clinical aspects].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10394185" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : [Uremic hemolytic syndrome. Analysis of 43 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8773646" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Survey of haemolytic-uraemic syndrome in Queensland 1979-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18465151" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008534" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090653" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7991042" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Outcome and prognostic determinants in the hemolytic uremic syndrome of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29961127" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24266872" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Laboratory predictors of acute dialysis in hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25149851" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1408519" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651320" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Predictors of fatality in postdiarrheal hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046736" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30466555" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Case definitions of hemolytic uremic syndrome following Escherichia coli O157:H7 infection vary in validity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257808" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871193" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Why antibiotics should not be used to treat Shiga toxin-producing Escherichia coli infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917812" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431799" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528561" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9092315" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1640303" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2181099" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25895445" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1843098" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Causes of death in hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9621207" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clostridium septicum infection and hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150928" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A 2-year-old boy with hemolytic uremic syndrome and pneumocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22736786" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A microbiological hazard of rural living: Clostridium septicum brain abscess in a child with E coli 0157 associated haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28183731" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : C septicum Complicating Hemolytic Uremic Syndrome: Survival Without Surgical Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630042" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34152955" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
